| Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma TK Choueiri, T Powles, M Burotto, B Escudier, MT Bourlon, B Zurawski, ... New England Journal of Medicine 384 (9), 829-841, 2021 | 1199 | 2021 |
| Avelumab, an anti–programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase ib study AB Apolo, JR Infante, A Balmanoukian, MR Patel, D Wang, K Kelly, ... Journal of Clinical Oncology 35 (19), 2117, 2017 | 627 | 2017 |
| Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial MR Patel, J Ellerton, JR Infante, M Agrawal, M Gordon, R Aljumaily, ... The Lancet Oncology 19 (1), 51-64, 2018 | 588 | 2018 |
| PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata: associations with localized stage progression BA Inman, TJ Sebo, X Frigola, H Dong, EJ Bergstralh, I Frank, Y Fradet, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2007 | 514 | 2007 |
| Phase II study of everolimus in metastatic urothelial cancer MI Milowsky, G Iyer, AM Regazzi, H Al-Ahmadie, SR Gerst, I Ostrovnaya, ... BJU international 112 (4), 462, 2013 | 186 | 2013 |
| Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer AB Apolo, J Riches, H Schöder, O Akin, A Trout, MI Milowsky, DF Bajorin Journal of clinical oncology 28 (25), 3973, 2010 | 184 | 2010 |
| Novel tracers and their development for the imaging of metastatic prostate cancer AB Apolo, N Pandit-Taskar, MJ Morris Journal of Nuclear Medicine 49 (12), 2031-2041, 2008 | 170 | 2008 |
| 696O_PR Nivolumab+ cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial TK Choueiri, T Powles, M Burotto, MT Bourlon, B Zurawski, VMO Juárez, ... Annals of Oncology 31, S1159, 2020 | 150 | 2020 |
| Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label … RJ Motzer, T Powles, M Burotto, B Escudier, MT Bourlon, AY Shah, ... The Lancet Oncology 23 (7), 888-898, 2022 | 149 | 2022 |
| Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer AV Balar, AB Apolo, I Ostrovnaya, S Mironov, A Iasonos, A Trout, ... Journal of clinical oncology 31 (6), 724, 2013 | 117 | 2013 |
| Multimodal management of muscle-invasive bladder cancer JC Park, DE Citrin, PK Agarwal, AB Apolo Current problems in cancer 38 (3), 80-108, 2014 | 109 | 2014 |
| Circulating tumor cells detection has independent prognostic impact in high‐risk non‐muscle invasive bladder cancer P Gazzaniga, E de Berardinis, C Raimondi, A Gradilone, GM Busetto, ... International journal of cancer 135 (8), 1978-1982, 2014 | 103 | 2014 |
| Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors AB Apolo, R Nadal, DM Girardi, SA Niglio, L Ley, LM Cordes, ... Journal of Clinical Oncology 38 (31), 3672-3684, 2020 | 102 | 2020 |
| Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy AB Apolo, I Ostrovnaya, S Halabi, A Iasonos, GK Philips, JE Rosenberg, ... Journal of the National Cancer Institute 105 (7), 499-503, 2013 | 95 | 2013 |
| The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology KA Kurdziel, JH Shih, AB Apolo, L Lindenberg, E Mena, YY McKinney, ... Journal of Nuclear Medicine 53 (8), 1175-1184, 2012 | 95 | 2012 |
| Multi-omics integration analysis robustly predicts high-grade patient survival and identifies CPT1B effect on fatty acid metabolism in bladder cancer V Vantaku, J Dong, CR Ambati, D Perera, SR Donepudi, CS Amara, ... Clinical Cancer Research 25 (12), 3689-3701, 2019 | 92 | 2019 |
| Prospective study evaluating Na18F PET/CT in predicting clinical outcomes and survival in advanced prostate cancer AB Apolo, L Lindenberg, JH Shih, E Mena, JW Kim, JC Park, A Alikhani, ... Journal of Nuclear Medicine 57 (6), 886-892, 2016 | 77 | 2016 |
| Repeatability of quantitative 18F-NaF PET: a multicenter study C Lin, T Bradshaw, T Perk, S Harmon, J Eickhoff, N Jallow, PL Choyke, ... Journal of nuclear medicine 57 (12), 1872-1879, 2016 | 76 | 2016 |
| Nivolumab+ cabozantinib (NIVO+ CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended … RJ Motzer, TK Choueiri, T Powles, M Burotto, MT Bourlon, JJ Hsieh, ... Journal of Clinical Oncology 39 (6_suppl), 308-308, 2021 | 74 | 2021 |
| A phase I study of TRC 105 anti‐endoglin (CD 105) antibody in metastatic castration‐resistant prostate cancer FH Karzai, AB Apolo, L Cao, RA Madan, DE Adelberg, H Parnes, ... BJU international 116 (4), 546-555, 2015 | 74 | 2015 |
